Embedded Files
DelveInsight's "Diabetes Pipeline Insight 2025" analysis delivers extensive perspectives on 200+ organizations and 200+ investigational therapies in the Diabetes pipeline environment. It encompasses Diabetes pipeline drug candidate profiles, spanning clinical and nonclinical development stages. The analysis additionally features Diabetes treatment evaluation by product classification, developmental phase, administration route, and molecular category. It further spotlights the dormant pipeline assets in this therapeutic domain.
Identify the most recent therapeutics and treatment modalities in the Diabetes Pipeline. Access DelveInsight's extensive analysis today! @ Diabetes Pipeline Outlook
Essential Highlights from the Diabetes Pipeline Analysis
Essential Highlights from the Diabetes Pipeline Analysis
On 16 October 2025, Eli Lilly and Company initiated an investigation designed to evaluate the safety of insulin lispro-aabc in adult subjects with Type 2 diabetes mellitus in India. The investigation will span approximately 33 weeks for individual participants, encompassing screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).
DelveInsight's Diabetes pipeline analysis reveals a dynamic landscape with 200+ active organizations engaged in advancing 200+ pipeline candidates for Diabetes management.
Prominent Diabetes pharmaceutical developers include vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc., among others.
Promising Diabetes Treatment Assets include Aspirin, DA-2811, Forxiga, TG103, among others.
Maintain leadership with the most current pipeline outlook for Diabetes. Acquire perspectives on clinical investigations, investigational treatments, and prominent organizations with DelveInsight @ Diabetes Treatment Drugs
The Diabetes Pipeline Analysis offers a disease background, pipeline landscape, and therapeutic evaluation of the principal pipeline candidates in this field. The Diabetes Pipeline Analysis additionally emphasizes the unaddressed medical needs concerning Diabetes.
Understanding Diabetes
Understanding Diabetes
Diabetes represents a chronic metabolic condition distinguished by elevated blood glucose concentrations resulting from the body's inability to synthesize or efficiently utilize insulin, a hormone critical for glucose regulation. The condition predominantly manifests in two primary variants: Type 1 diabetes, an autoimmune disorder wherein the immune system attacks insulin-producing cells within the pancreas, and Type 2 diabetes, which is more prevalent and frequently linked with insulin resistance and lifestyle elements including obesity and inadequate nutrition. Additional variants encompass gestational diabetes, which develops during pregnancy, and less common forms including Maturity-Onset Diabetes of the Young (MODY) and Latent Autoimmune Diabetes in Adults (LADA).
Diabetes Investigational Drug Profiles
Diabetes Investigational Drug Profiles
Cadisegliatin: vTv Therapeutics
Cadisegliatin, alternatively designated as TTP399, represents an innovative oral agent developed by vTv Therapeutics, engineered as a liver-selective glucokinase activator. It is designed to function as an adjunctive treatment to insulin for individuals with type 1 diabetes (T1D). This therapeutic has gained recognition for its capability to enhance glycemic management by augmenting hepatic glucose uptake and glycogen storage independently of insulin, addressing a vital requirement in diabetes care. Presently, this agent is undergoing Phase III clinical evaluation for Diabetes management.
LY-3209590: Eli Lilly and Company
Insulin efsitora alfa (LY3209590) represents a once-weekly basal insulin, a fusion protein combining a novel single-chain insulin variant with a human IgG2 Fc domain. It is uniquely engineered for once-weekly subcutaneous delivery, and with its reduced peak-to-trough ratio, it demonstrates potential to deliver more consistent glucose concentrations (reduced glucose variability) throughout the week. Efsitora is currently in phase III development for adults diagnosed with type 1 and 2 diabetes.
CT-388: Roche
CT-388 represents a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist under development for obesity and type 2 diabetes (T2D) management. CT-388 was engineered to demonstrate robust activity on both GLP-1 and GIP receptors while exhibiting minimal to negligible β-arrestin recruitment on either receptor. This biased signaling substantially reduces receptor internalization and subsequent desensitization, which is anticipated to produce extended pharmacological activity. Presently, this therapeutic is undergoing Phase II clinical evaluation for Type 2 Diabetes Mellitus management.
HU6: Rivus Pharmaceuticals
HU6 represents an investigational, first-in-class oral treatment developed by Rivus Pharmaceuticals. It belongs to an innovative drug category termed Controlled Metabolic Accelerators (CMAs), engineered to selectively enhance fat metabolism, producing fat reduction while maintaining muscle mass. HU6 operates by modestly increasing resting metabolism, specifically by activating a mechanism termed mitochondrial uncoupling. This mechanism enhances the oxidation of sugars and fats without diminishing ATP (energy) generation, producing selective reduction of accumulated adipose tissue throughout the body. Presently, this therapeutic is in Phase II developmental stage for Diabetes treatment.
XW014: Sciwind Biosciences
XW014 represents an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist developed by Sciwind Biosciences for obesity and Diabetes (T2D) management. XW014 operates as a GLP-1 receptor agonist, indicating it replicates the function of the GLP-1 hormone released following meals. This hormone fulfills a critical role in glucose metabolism regulation by stimulating insulin secretion, suppressing glucagon release, and enhancing satiety. As an oral small molecule, XW014 provides benefits over conventional peptide-based GLP-1 treatments, including ease of administration and potential for combination regimens with other oral agents. Presently, this therapeutic is undergoing Phase I clinical evaluation for Diabetes management.
K-833: Kallyope Inc.
K-833 represents an investigational oral small-molecule developed by Kallyope Inc., engineered as a nutrient receptor agonist for obesity and type 2 diabetes management. K-833, frequently investigated in combination with Kallyope's additional candidate K-757, targets G-protein coupled receptors (specifically GPR119), which participate in the release of hormones that suppress appetite and modulate glucose. Presently, this therapeutic is undergoing Phase I clinical evaluation for Diabetes management.
Discover revolutionary treatments and clinical investigations in the Diabetes Pipeline. View DelveInsight's comprehensive analysis now! @ New Diabetes Drugs
The Diabetes Pipeline Analysis Delivers Perspectives on
The Diabetes Pipeline Analysis Delivers Perspectives on
The analysis offers comprehensive insights regarding organizations advancing treatments for Diabetes management with aggregate therapeutic candidates developed by individual companies for this indication.
It evaluates various therapeutic assets categorized into initial-stage, intermediate-stage, and advanced-stage development for Diabetes Treatment.
Diabetes pharmaceutical developers engaged in targeted therapeutic advancement with corresponding active and inactive (dormant or terminated) programs.
Diabetes therapeutics under investigation are classified by development phase, administration route, target receptor, monotherapy or combination approaches, distinct mechanisms of action, and molecular classification.
Comprehensive examination of partnerships (inter-company collaborations and company-academic institution partnerships), licensing agreements and funding arrangements for future progression of the Diabetes market.
Diabetes Pharmaceutical Developers
Diabetes Pharmaceutical Developers
vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. among others.
The Diabetes pipeline analysis delivers therapeutic classification of pipeline candidates by Administration Route. Assets have been organized across various administration methods including:
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Diabetes Assets have been categorized across various Molecular classifications including:
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Reveal the future of Diabetes Treatment. Discover innovative therapeutics, pipeline advancements, and principal organizations with DelveInsight's expert examination @ Diabetes Market Drivers and Barriers
Parameters of the Diabetes Pipeline Analysis
Parameters of the Diabetes Pipeline Analysis
Geographic Coverage: Global
Diabetes Pharmaceutical Organizations: vTv Therapeutics, Eli Lilly and Company, Sciwind Biosciences, AstraZeneca, Neurodon, Regor Therapeutics, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Roche, Rivus Pharmaceuticals, Kallyope Inc. among others.
Diabetes Treatment Assets: Aspirin, DA-2811, Forxiga, TG103, among others.
Diabetes Treatment Evaluation by Product Classification: Monotherapy, Combination therapy, Monotherapy/Combination therapy
Diabetes Treatment Evaluation by Clinical Phases: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Access the most recent information on Diabetes Treatments and clinical investigations. Download DelveInsight's comprehensive pipeline analysis today! @ Diabetes Companies, Key Products and Unmet Needs
Report Contents
Report Contents
* Introduction
* Executive Summary
* Diabetes: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Diabetes- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Cadisegliatin: vTv Therapeutics
* Drug profiles in the detailed report.....
* Mid-Stage Products (Phase II)
* CPL207280: Celon Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* KN056: Suzhou Alphamab Co., Ltd.
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Diabetes Key Companies
* Diabetes Key Products
* Diabetes- Unmet Needs
* Diabetes- Market Drivers and Barriers
* Diabetes- Future Perspectives and Conclusion
* Diabetes Analyst Views
* Diabetes Key Companies
* Appendix
About Us
About Us
DelveInsight operates as a premier healthcare-oriented market research and advisory organization delivering high-caliber market intelligence and strategic analysis to support evidence-based business planning. Supported by a team of seasoned industry specialists and comprehensive expertise in life sciences and healthcare domains, we deliver tailored research solutions and strategic insights to clients worldwide. Partner with us to access premium, precise, and real-time intelligence for maintaining competitive advantage.
Contact Us
Contact Us
Kanishk
kkumar@delveinsight.com
Page updated
Google Sites
Report abuse